An international perspective on anticholinergic therapy

doi:10.1016/S0002-9343(96)80013-1

The American Journal of Medicine

Volume 100, Supplement 1, 29 January 1996, Pages S2-S4

https://doi.org/10.1016/S0002-9343(96)80013-1 Get rights and content

Since the introduction of inhaled quaternary anticholinergic bronchodilators, their clinical usefulness has been explored in a variety of settings. They have emerged as the inhaled bronchodilators of first choice in the management of chronic obstructive pulmonary disease (COPD). In other countries, they have also found an adjunctive role in the management of asthma. This may be best seen in the treatment of acute asthma where the combination of anticholinergic and adrenergic bronchodilators appear more effective than single-agent inhalation therapy. This finding appears consistently in large studies, whether in adult or pediatric populations. Such combination nebulizer therapy would appear to be cost effective, but further study is required.

References (19)

RuffinR.E. et al.
A comparison of the bronchodilator activity of Sch 1000 and salbutamol
J Allergy Clin Immunol
(1977)
LightbodyI.M. et al.
Ipratropium bromide, salbutamol and prednisolone in bronchial asthma and chronic bronchitis
Br J Dis Chest
(1978)
LefcoeN.M. et al.
The addition of an aerosol anticholinergic to an oral β-agonist plus theophylline in asthma and bronchitis. A double-blind single dose study
Chest
(1982)
RebuckA.S. et al.
Anticholinergic and sympathomimetic combination therapy of asthma
J Allergy Clin Immunol
(1983)
WardM.J. et al.
A place for ipratropium bromide in the treatment of severe acute asthma
Br J Dis Chest
(1985)
LeahyB.E. et al.
Comparison of nebulized salbutamol with nebulized ipratropium bromide in acute asthma
Br J Dis Chest
(1983)
RebuckA.S. et al.
Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room
Am J Med
(1987)
BryantD.H.
Nebulized Ipratropium bromide in the treatment of acute asthma
Chest
(1985)
BeckR. et al.
Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma
J Pediatr
(1985)

There are more references available in the full text version of this article.

Cited by (14)

Combined inhaled anticholinergics and short-acting beta<inf>2</inf>-agonists for initial treatment of acute asthma in children
2013, Paediatric Respiratory Reviews
The role of ipratropium bromide in the emergency management of acute asthma exacerbation: A metaanalysis of randomized clinical trials
1999, Annals of Emergency Medicine
Study objective: This study was conducted to determine whether the addition of inhaled ipratropium to inhaled β-agonist therapy is effective in the treatment of adults with acute asthma exacerbation. Methods: Published reports of randomized, controlled trials assessing the use of ipratropium and β-agonists in asthma were identified by a search of the MEDLINE, EMBASE, CINAHL, Biological Abstracts on CD, the Cochrane Library, and Current Contents databases. Bibliographies from identified studies and from review articles were manually searched. Published and unpublished reports in English, French, and Italian were identified and assessed for inclusion in the metaanalysis. Randomized, double-blind, placebo-controlled trials were selected in which ipratropium was used as adjunctive therapy to β-agonists in adult patients with acute asthma exacerbation presenting to a hospital emergency department or similar acute care setting. Data were extracted independently by 2 reviewers. For eligible trials, the mean percent change in peak expiratory flow rate (PEFR), or forced expiratory volume in one second (FEV ₁ ), and their SDs were assessed in the ipratropium-treated and control groups. The effect of ipratropium on hospitalization rates and adverse effects were also analyzed. Results: Data from 10 studies, reporting on a total of 1,377 patients with asthma, were pooled using a weighted average method. Compared with placebo, the use of ipratropium was associated with a pooled 7.3% improvement in FEV ₁ (95% confidence interval [CI] 3.8% to 10.9%), corresponding to an absolute improvement in FEV ₁ in the ipratropium/ β-agonist group, which was 100 mL (95% CI 50 to 149 mL) above that seen for the group that received β-agonist without ipratropium. Similarly, the pooled estimate of treatment effect in trials that reported data as PEFR was 22.1% (95% CI 11.0% to 33.2%), corresponding to an absolute peak expiratory flow improvement of 32 L/min (95% CI 16 to 47 L/min) in favor of the ipratropium/ β-agonist combination group. When these data were combined using effect size as a common measure, the use of ipratropium was associated with a summary effect size of .38 (95% CI .27 to .48). Effect sizes were negatively correlated with baseline mean expiratory flows, suggesting that studies enrolling patients with more severe airflow obstruction showed greater absolute benefits of combination bronchodilator therapy. For the 3 trials reporting hospital admission data (n=1,031), patients receiving ipratropium had a relative risk of hospitalization of .73 (95% CI .53 to .99). The use of ipratropium was not associated with any severe adverse effects when used in conjunction with β ₂ -agonists. Conclusion: There is a modest statistical improvement in airflow obstruction when ipratropium is used as an adjunctive treatment to β ₂ -agonists for the treatment of acute asthma exacerbation. Although the clinical significance of this improvement in airflow obstruction remains unclear, it would seem reasonable to recommend the use of combination ipratropium/ β-agonist therapy in acute adult asthmatic exacerbations, since the addition of ipratropium seemed to provide physiologic evidence of benefit without risk of adverse effects.[Stoodley RG, Aaron SD, Dales RE: The role of ipratropium bromide in the emergency management of acute asthma exacerbation: A metaanalysis of randomized clinical trials. Ann Emerg Med July 1999;34:8-18.]
Selective muscarinic M<inf>1</inf> antagonists: Drug design and discovery
1997, Drug Discovery Today
Years of clinical research to treat disorders such as peptic ulcers and obstructive lung disease with the first generation of modestly selective M₁ antagonists (e.g. pirenzepine, telenzepine) have been disappointing. For some indications (chronic obstructive pulmonary disease), nonselective antagonists (ipratropium bromide) have exhibited better clinical efficacy. The advent of a new generation of centrally active and highly selective M₁ antagonists, such as PD150714, spirotramine FC1594, (-)-S-ET126 and R-4-(pyrrolidino)-1-(4-fluorophenylcarbamoyloxy)-1-phenyl-2-butyne (4-F-PhPyMcN), offers new opportunities for using selective muscarinic agents as therapeutic agents or research tools.
The current role of ipratropium bromide in an acute exacerbation of asthma
2015, Journal of Paediatrics and Child Health
Inhaled anticholinergics and short-acting beta<inf>2</inf>-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital
2014, Cochrane Database of Systematic Reviews
Combined inhaled anticholinergics and short-acting beta<inf>2</inf>-agonists for initial treatment of acute asthma in children
2013, Cochrane Database of Systematic Reviews

View all citing articles on Scopus

View full text

An international perspective on anticholinergic therapy

J Allergy Clin Immunol

Br J Dis Chest

Chest

J Allergy Clin Immunol

Br J Dis Chest

Br J Dis Chest

Am J Med

Chest

J Pediatr